Table 2.

Two-year clinical event rates in BIO-RESORT and BIONYX trial participants with known diabetes.

	BIO-RESORT patients with diabetes (N = 624)							BIONYX patients with diabetes (N = 510)
	SES N = 211	RI-ZES N = 210	EES N = 203	Hazard ratio (95% CI) SES vs. RI-ZES	P-logrank SES vs. RI-ZES	Hazard ratio (95% CI) EES vs. RI-ZES	P-logrank EES vs. RI-ZES	SES N = 250	RO-ZES N = 260	Hazard ratio (95% CI) SES vs. RO-ZES	P-logrank SES vs. RO-ZES
Cardiac death	3 (1.5)	9 (4.4)	4 (2.0)	0.32 (0.09–1.19)	0.07	0.45 (0.14–1.44)	0.17	7 (2.9)	7 (2.8)	1.05 (0.37–2.99)	0.93
Target vessel myocardial infarction	6 (2.9)	7 (3.4)	10 (5.0)	0.84 (0.28–2.51)	0.76	1.48 (0.56–3.87)	0.43	11 (4.5)	11 (4.4)	1.05 (0.46–2.43)	0.90
Target vessel revascularization	16 (7.8)	13 (6.5)	8 (4.1)	1.21 (0.58–2.52)	0.61	0.60 (0.25–1.46)	0.26	14 (5.8)	20 (8.0)	0.73 (0.37–1.44)	0.36
Target lesion revascularization	10 (4.8)	6 (3.0)	7 (3.6)	1.65 (0.60–4.53)	0.33	1.17 (0.39–3.47)	0.78	9 (3.7)	15 (6.0)	0.62 (0.27–1.42)	0.25
Target vessel failure⁎	21 (10.2)	26 (12.7)	20 (10.0)	0.79 (0.44–1.40)	0.42	0.78 (0.44–1.40)	0.40	26 (10.7)	31 (12.2)	0.88 (0.52–1.48)	0.63
Target lesion failure	15 (7.2)	20 (9.7)	19 (9.5)	0.73 (0.38–1.43)	0.36	0.97 (0.52–1.83)	0.93	21 (8.7)	26 (10.2)	0.84 (0.47–1.50)	0.56
Definite-or-probable stent thrombosis	3 (1.4)	4 (1.9)	3 (1.5)	0.75 (0.17–3.34)	0.70	0.76 (0.17–3.38)	0.71	4 (1.6)	1 (0.4)	4.18 (0.47–37.43)	0.16
Definite stent thrombosis	3 (1.4)	1 (0.5)	3 (1.4)	2.99 (0.31–28.70)	0.32	2.00 (0.18–22.01)	0.57	3 (1.2)	1 (0.4)	3.14 (0.33–30.18)	0.30

Data are n (%).

Abbreviations: CI = confidence interval; EES = Synergy everolimus-eluting stent; RI-ZES = Resolute Integrity zotarolimus-eluting stent; RO-ZES = Resolute Onyx zotarolimus-eluting stent; SES = Orsiro sirolimus-eluting stent.

^⁎Target vessel failure is the main endpoint consisting of cardiac death, target vessel myocardial infarction, or target vessel revascularization.